[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]

Area of Science:

• Oncology
• Dermatology
• Endocrinology

Background:

• Bexarotene is a retinoid X receptor agonist used for cutaneous T-cell lymphoma.
• Common side effects include hypothyroidism and hyperlipidemia.
• The impact on HDL-cholesterol is less characterized.

Observation:

• Three patients treated with bexarotene experienced significant reductions in HDL-cholesterol.
• These patients also presented with central hypothyroidism and severe mixed hyperlipidemia.
• The observed decrease in HDL-cholesterol averaged over 83%.

Findings:

• Bexarotene induces severe mixed hyperlipidemia and central hypothyroidism.
• A marked decrease in HDL-cholesterol is a consistent and significant adverse event.
• These effects are reversible and dose-dependent.

Implications:

• Understanding bexarotene's impact on lipid profiles, particularly HDL-cholesterol, is crucial.
• Management strategies may require adjustments to address these metabolic complications.
• Further research into the mechanisms and clinical significance of bexarotene-induced dyslipidemia is warranted.